ECTRIMS 2024: Tolebrutinib may target smoldering inflammation
WEB17 hours ago · The findings were presented in a pair of Sanofi-sponsored late-breaking presentations at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting, which was ...
Press Room - Sanofi US News
WEB4 days ago · About Multiple Sclerosis Multiple sclerosis is a chronic, immune-mediated, neurodegenerative disease that results in accumulation of irreversible disabilities over time. The physical and cognitive disability impairments translate into gradual deterioration of health status and lower quality of life, impacting patients’ care and life expectancy.
Sanofi lifts lid on data behind tolebrutinib’s mixed MS studies
WEB3 days ago · Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate tolebrutinib, linking the BTK inhibitor to a 31% delay in time to onset of ...
Sanofi presents new data from robust MS clinical pipeline …
WEBOct 2, 2023 · Sanofi will present new data at the 9 th Joint ECTRIMS-ACTRIMS meeting evaluating three investigational treatments for multiple sclerosis (MS) that target the underlying biology of MS to treat the full spectrum of disease and reinforce the commitment to address smoldering neuroinflammation, a key driver of disability progression.
Tolebrutinib clinical trial program update - Sanofi
WEBAug 8, 2022 · The relapsing MS trials in the tolebrutinib clinical trial program, GEMINI I and GEMINI II, are now fully enrolled. Regulatory timelines for this indication remain unchanged with submission in relapsing MS expected in 2024.
Multiple sclerosis pill succeeds in key trial, Sanofi says - STAT
WEBSep 2, 2024 · Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies,...
BTK Inhibitor Tolebrutinib Slows Disability Progression in Phase 3 ...
WEBSep 3, 2024 · Tolebrutinib, a brain-penetrant BTK inhibitor, achieved the primary endpoint in the HERCULES study, significantly reducing disability accumulation in patients with non-relapsing secondary progressive multiple sclerosis. Houman Ashrafian, MD, PhD. Sanofi has announced topline data from its phase 3 HERCULES study (NCT04411641) of its ...
Sanofi's tolebrutinib cuts MS progression by 31% in trial
WEB3 days ago · Sanofi has bolstered the case for its oral BTK inhibitor tolebrutinib as a treatment for multiple sclerosis (MS), due to be filed for approval in the latter half of this year, with new data in a ...
Sanofi eyes approval after MS therapy slows disease progression …
WEB3 days ago · SNY. Sanofi is eyeing global regulatory approval for tolebrutinib after releasing positive Phase III data in non-relapsing secondary progressive multiple sclerosis (MS), The results from the ...
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
WEB3 days ago · SNY. By Ludwig Burger. FRANKFURT (Reuters) -Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French ...